SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates.

ABSTRACT:

Background

This study aimed to show that SHOX2 DNA methylation is a tumor marker in patients with suspected lung cancer by using bronchial fluid aspirated during bronchoscopy. Such a biomarker would be clinically valuable, especially when, following the first bronchoscopy, a final diagnosis cannot be established by histology or cytology. A test with a low false positive rate can reduce the need for further invasive and costly procedures and ensure early treatment.

Methods

Marker discovery was carried out by differential methylation hybridization (DMH) and real-time PCR. The real-time PCR based HeavyMethyl technology was used for quantitative analysis of DNA methylation of SHOX2 using bronchial aspirates from two clinical centres in a case-control study. Fresh-frozen and Sacc

SUBMITTER: Schmidt B 

PROVIDER: S-EPMC2988753 | biostudies-literature | 2010 Nov

REPOSITORIES: biostudies-literature